Squamous Cell Carcinoma of the Skin Clinical Trial
Official title:
Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study
This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy of camrelizumab (PD-1 mab) combined with cisplatin in the treatment of advanced CSCC.
This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy, safety and quality of life of patients with advanced CSCC treated with camrelizumab (PD-1 mab) combined with cisplatin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Active, not recruiting |
NCT06327971 -
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
|
||
| Not yet recruiting |
NCT03621462 -
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
|
N/A | |
| Not yet recruiting |
NCT04480645 -
CivaDerm(TM) Surface Therapy Pilot Study
|
Early Phase 1 | |
| Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
| Recruiting |
NCT06014086 -
Intratumoral PH-762 for Cutaneous Carcinoma
|
Phase 1 | |
| Completed |
NCT02347813 -
Preventing Squamous Cell Skin Cancer
|
Phase 2 | |
| Terminated |
NCT01984892 -
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
|
Phase 2 | |
| Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT04204837 -
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
| Completed |
NCT03894618 -
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
| Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
| Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT05246228 -
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
|
||
| Recruiting |
NCT05886140 -
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
|
N/A | |
| Completed |
NCT02324608 -
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
|
N/A | |
| Recruiting |
NCT02717936 -
Investigation of Desmoplastic Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
| Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 |